Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
illi News/10298561

Trending...
CHENGDU, China, April 24, 2025 ~ Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) has announced that it will be showcasing the results of six clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3. These studies, led by Kelun, include data from their TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031).

The abstracts for these studies will be published on ASCO's official website on May 22, 2025, local time. The selected studies for ASCO 2025 are focused on various types of cancer and aim to present promising treatment options for patients.

One of the studies, titled "Sacituzumab tirumotecan (sac-TMT) in patients with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study," will be presented as an oral presentation on June 1st. This study focuses on the use of sac-TMT as a potential treatment option for patients with advanced NSCLC.

More on illi News
Another study, titled "Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study," will also be presented as an oral presentation on May 31st. This study looks at the effectiveness of tagitanlimab in combination with other treatments for patients with recurrent or metastatic nasopharyngeal carcinoma.

The Phase II OptiTROP-Breast05 study will also be presented as a rapid oral presentation on May 30th. This study focuses on the use of sac-TMT as a first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC).

In addition to these presentations, there will also be a poster presentation on May 31st for the study titled "Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study." This study looks at the potential of combining sac-TMT and tagitanlimab as a first-line treatment option for patients with advanced NSCLC.

More on illi News
The remaining two studies, "Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study" and "Results from a phase I study of KL590586 in patients with advanced RET-mutant medullary thyroid cancer," will both be presented as poster presentations on May 31st and June 2nd respectively.

These studies demonstrate Kelun's commitment to developing innovative treatments for various types of cancer. The results presented at ASCO 2025 have the potential to significantly impact the lives of patients and improve their outcomes. The company looks forward to sharing their findings with the medical community at this prestigious event.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on illi News